Betaxolol hydrochloride

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

200 mg, 3 times a day Modified release: 400 mg daily

PHARMACOKINETICS

  • Molecular weight                           :361.8
  • %Protein binding                           :95
  • %Excreted unchanged in urine     : 50
  • Volume of distribution (L/kg)       :0.24–0.35
  • half-life – normal/ESRD (hrs)      :1–2 (XL: 3.4)/7.8–20

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    40–60 400 mg daily15–40 200 mg every 24–48 hours<15 Avoid

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. 200 mg every 72 hours
  • HD                     :Not dialysed. 200 mg every 72 hours
  • HDF/high flux   :Unknown dialysability. 200 mg every 72 hours
  • CAV/VVHD      :Unknown dialysability. Dose as in GFR=15–40 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAntibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant useAnticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and adjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureasCiclosporin: may increase nephrotoxicity and reduce ciclosporin levelsLipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe – avoid with ezetimibe; do not exceed 10 mg of simvastatin1

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Take dose with or after food Contraindicated in nephrotic syndrome There should be an interval of 2 hours between intake of ion exchange resin and bezafibrateModified-release preparation is not appropriate in renal impairment

  • Related News